Scarica l'app Stockscreener
14.60
0.95%
-0.14
Dopo l'orario di chiusura:
14.60
Precedente Chiudi:
$14.74
Aprire:
$14.77
Volume 24 ore:
269.89K
Relative Volume:
0.56
Capitalizzazione di mercato:
$1.01B
Reddito:
$62.71M
Utile/perdita netta:
$-112.51M
Rapporto P/E:
-9.6689
EPS:
-1.51
Flusso di cassa netto:
$-96.01M
1 W Prestazione:
+0.07%
1M Prestazione:
-0.27%
6M Prestazione:
+39.58%
1 anno Prestazione:
+34.69%
Intervallo 1D:
$14.48
$14.97
Intervallo di 1 settimana:
$14.26
$15.08
Portata 52W:
$7.97
$17.70
Zymeworks Inc. Stock (ZYME) Company Profile
Nome
Zymeworks Inc.
Settore
Industria
Telefono
604-678-1388
Indirizzo
1385 West 8th Avenue, Suite 540, Vancouver, BC
Confronta ZYME con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ZYME
Zymeworks Inc.
|
14.60 | 1.01B | 62.71M | -112.51M | -96.01M | -1.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Zymeworks Inc. Stock (ZYME) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-16 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2024-11-07 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-11-01 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2023-03-21 | Ripresa | Wells Fargo | Overweight |
| 2023-01-04 | Reiterato | H.C. Wainwright | Neutral |
| 2022-12-20 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-01 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-10-21 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-10-04 | Ripresa | Wells Fargo | Overweight |
| 2022-05-05 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-03-15 | Iniziato | Evercore ISI | Outperform |
| 2021-12-10 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-17 | Ripresa | Guggenheim | Neutral |
| 2021-10-07 | Iniziato | Jefferies | Hold |
| 2021-03-31 | Iniziato | Credit Suisse | Outperform |
| 2021-02-25 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2021-02-08 | Ripresa | H.C. Wainwright | Buy |
| 2021-01-25 | Downgrade | Citigroup | Buy → Neutral |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-06 | Iniziato | SVB Leerink | Outperform |
| 2020-01-10 | Iniziato | Wolfe Research | Outperform |
| 2019-12-09 | Iniziato | JP Morgan | Neutral |
| 2019-11-25 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-20 | Iniziato | Guggenheim | Buy |
| 2019-09-30 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2019-08-30 | Iniziato | Stifel | Buy |
| 2019-07-18 | Iniziato | Deutsche Bank | Buy |
| 2018-05-11 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2018-03-19 | Iniziato | Raymond James | Outperform |
Mostra tutto
Zymeworks Inc. Borsa (ZYME) Ultime notizie
Zymeworks to Engage Investors at Key Conferences - TipRanks
Zymeworks Announces Participation in Upcoming Investor Conferences - The Manila Times
Cancer Drug Developer Zymeworks Takes Center Stage at Oppenheimer, Citi, and B. Riley Events - StockTitan
Zymeworks (NASDAQ:ZYME) shareholder returns have been respectable, earning 79% in 3 years - Simply Wall St
The past five years for Zymeworks (NASDAQ:ZYME) investors has not been profitable - Yahoo Finance
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Buys 19,748 Shares - MarketBeat
Zymeworks Inc. (NYSE:ZYME) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
Analysts Set Zymeworks Inc. (NYSE:ZYME) PT at $19.17 - MarketBeat
EcoR1 Capital, LLC Expands Stake in Zymeworks Inc with Strategic Acquisition - GuruFocus.com
Assenagon Asset Management S.A. Raises Position in Zymeworks Inc. (NYSE:ZYME) - Defense World
Assenagon Asset Management S.A. Boosts Stake in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Engineered Multispecific Antibodies Innovation Research Report 2024: Patent Trends Show a Noticeable Surge in 2023 with Regeneron, Roche, and Amgen Emerging as the Top Patent Filers - GlobeNewswire Inc.
Zymeworks (NYSE:ZYME) Shares Gap Up Following Insider Buying Activity - Defense World
Opinion: Four trends to watch in B.C.'s tech sector - Business in Vancouver
Zymeworks (NYSE:ZYME) Shares Gap Up on Insider Buying Activity - MarketBeat
EcoR1 Capital, LLC Increases Stake in Zymeworks Inc - GuruFocus.com
ZYME (Zymeworks) Total Stockholders Equity : $366.98 Mil (As of Sep. 2024) - GuruFocus.com
Insider Buying: Zymeworks Inc. (NYSE:ZYME) Director Acquires 74,125 Shares of Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock By Investing.com - Investing.com Nigeria
Ecor1 Capital, Llc Buys 39,029 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital acquires $2.28 million in Zymeworks stock - Investing.com
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase By Investing.com - Investing.com South Africa
Zymeworks Inc. (NYSE:ZYME) Director Ecor1 Capital, Llc Acquires 204,098 Shares of Stock - MarketBeat
Ecor1 Capital, Llc Purchases 21,021 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Ecor1 capital increases stake in Zymeworks with $2.97 million purchase - Investing.com
Zymeworks in Focus for Insider Activity: Catalysts Ahead - Benzinga
Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026 - The Manila Times
Zymeworks Sets Strategic Milestones for 2025-2026 with Focus on Novel Therapeutics - TipRanks
Zymeworks says it has enough cash to operate through H2 2027 - Seeking Alpha
Zymeworks Unveils 2025 Pipeline Strategy: Multiple INDs Planned, $324M Cash Position Supports Growth - StockTitan
Wall Street Analysts Believe Zymeworks (ZYME) Could Rally 41.36%: Here's is How to Trade - Yahoo Finance
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock By Investing.com - Investing.com Australia
Zymeworks chief scientific officer sells shares worth $316,390 By Investing.com - Investing.com Australia
Zymeworks Inc. (NYSE:ZYME) CEO Sells $854,781.72 in Stock - MarketBeat
Insider Selling: Zymeworks Inc. (NYSE:ZYME) EVP Sells 11,110 Shares of Stock - MarketBeat
Paul Andrew Moore Sells 21,200 Shares of Zymeworks Inc. (NYSE:ZYME) Stock - MarketBeat
Zymeworks chief scientific officer sells shares worth $316,390 - Investing.com
Zymeworks CEO Kenneth Galbraith sells $855,016 in stock - Investing.com
Zymeworks (NYSE:ZYME) Shares Gap Up After Insider Buying Activity - Defense World
Zymeworks Inc. Azioni (ZYME) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.95%
2.39%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):